Nice announcement, will keep them afloat and help reach their revenue target.
However targeting the clinical trial market (after all these years) doesn't excite the market, because of the one-off revenue from the contract. Also how big is this market?
Cdx needs recurring revenue, and the faster they transition to a SaaS model and cut costs the better.
